Friday, March 11, 2022

The Truth About Gardisil - For people who love to say Vaccines can't possibly be harmful

You can see more information about Gardisil lawsuits, HERE.


The following article from Children's Health Defense can be seen on their website, via this link... please consider subscribing to their informative newsletter. It's a real eye-opener!

https://childrenshealthdefense.org/defender/merrick-brunker-merck-lawsuit-gardasil-hpv-vaccine/?utm_source=salsa&eType=EmailBlastContent&eId=7db0d56d-7e51-4b45-84ed-2c5ad9c409af

03/11/22

Young Man Sues Merck, Wants Accountability for Injuries Caused by Gardasil HPV Vaccine

Merrick Brunker was a “happy, healthy” 18-year-old before he received Merck’s Gardasil HPV vaccine. Now, he’s no longer physically active, cannot participate in sports and other activities, no longer attends school and has had trouble finding work.

Miss a day, miss a lot. Subscribe to The Defender's Top News of the DayIt's free.

Attorneys from Baum Hedlund Aristei & Goldman and Robert F. Kennedy, Jr., chairman of Children’s Health Defense, filed their 14th lawsuit against Merck alleging the drugmaker knowingly concealed adverse events associated with its Gardasil HPV vaccine.

The lawsuit was filed last month on behalf of Merrick Brunker, in the Superior Court of the State of California, Ventura County.

Brunker was 18 years old and had just graduated from high school when he received the Gardasil vaccine. At the time, he was a happy, healthy young man who enjoyed surfing, hiking, working out, playing basketball, going to the movies, building things around his family’s house, working on his car and playing several musical instruments.

Minutes after receiving the vaccine, Merrick reported an odd taste in his mouth, felt dizzy and almost fainted. Six days later, he went to the doctor to report extreme headaches, intermittent tingling in his legs, numbness and feeling like he was blacking out.

Brunker’s symptoms were so severe he could not walk.

Merrick’s doctor performed a lumbar puncture and removed some fluid to help with his symptoms. A week after the lumbar puncture, Merrick returned to the doctor with his father. When the doctor came in to examine him, Merrick was lying down with the lights off and a towel over his face.

Merrick said he was having headaches, weakness, muscle spasms, nausea, sharp pains to the chest and sensitivity to light and noise.

Within months, Merrick’s symptoms included:

  • Chest pain and pressure.
  • Chronic fatigue.
  • Headaches.
  • Abnormal resting heart rate.
  • Muscle spasms.
  • Tingling in arms and legs.
  • Severe weight loss.
  • Insomnia.
  • Cold sweats.
  • Sensory sensitivity.
  • Anxiety.
  • Depression.

Merrick was never told the Gardasil vaccine could cause the symptoms he was experiencing.

Merrick is now 23 years old. His post-Gardasil health problems prevent him from activities that a young man his age would normally enjoy.

He is no longer physically active, cannot participate in sports and other activities as he once did, no longer attends school and has had trouble finding work.

Doctors diagnosed Merrick with chronic fatigue syndrome (CFS), depression and anxiety.

“I don’t think Merck has any regard for me or thousands of other people like me who suffer from post-Gardasil injuries,” Merrick said. “I don’t think they care that they’ve destroyed our chance at pursuing the life we want. “

“It’s time for them to answer for all of this and be held accountable for what they’ve done,” Merrick added.

This is the 14th lawsuit filed by Baum Hedlund and Kennedy against Merck for knowingly concealing the adverse events associated with its Gardasil vaccine. Others include:

All of these clients have unique stories, but they all agree if Merck had told the truth about the known dangers associated with Gardasil, they never would have consented to the HPV vaccine.

If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Baum Hedlund Law for a free case evaluation, or call 844-RFK-HPV1.



Lead Expert of HPV Vaccine Tells the Truth About Gardasil and Cervarix

Dr. Diane Harper was a leading developer and expert responsible for the Phase II and Phase III safety and effectiveness studies, which gained the approval of the human papilloma virus ("HPV") vaccines, Gardasil and Cervarix. Since the HPV vaccine has been approved by the FDA and gained popularity, Dr. Harper has publicized the serious consequences, as well as the ineffectiveness, of these vaccines.

Dr. Harper made her shocking statement at the 4th International Conference on Vaccination, which took place on October 2, 2009 in Reston, Virginia. Reportedly, her speech was supposed to support the Gardasil and Cervarix vaccines, but instead she decided to clear her conscience about the deadly vaccines, in public, so she “could sleep at night.”

Dr. Harper explained in her presentation that the risk of cervical cancer in the U.S. is already very low and that vaccinations are unlikely to have any effect upon the rate of cervical cancer in the United States.  In fact, 70 percent of all HPV infections resolve themselves without treatment in a year, and the number rises to well over 90 percent in two years. Remarkably, all the trials of the vaccines were done on children aged 15 and older, despite them currently being marketed for 9-year-olds.

At least 15,037 girls have reported adverse side effects just from Gardasil to the Vaccine Adverse Event Reporting System (VAERS), and this number only reflects those who underwent all the requirements for reporting adverse reactions.  Moreover, according to the latest VAERS Report, 139 deaths from girls treated with the HPV related vaccinations are officially known. At the time of Dr. Harper’s speech, it was recorded to be 44 deaths.  Some of the other reported side effects include Guillain-Barre Syndrome, lupus, seizures, blood clots, and brain inflammation. In most cases, parents are not made aware of these risks.

Dr. Diane Harper went on to say, “About eight in every ten women who have been sexually active will have HPV at some stage of their life. Normally there are no symptoms, and in 98 percent of cases it clears itself. But in those cases where it doesn’t, and isn’t treated, it can lead to precancerous cells which may develop into cervical cancer.

There is no actual evidence that the vaccine can prevent any cancer. From the manufacturers own admissions, the vaccine only works on 4 strains out of 40 for a specific venereal disease that dies on its own in a relatively short period, so the chance of it actually helping an individual is about the same as the chance of her being struck by lightningIs it really necessary for a 9-year-old girl to receive a vaccination for an extremely rare and symptomless venereal disease that the immune system usually kills anyway? Are pharmaceutical companies placing profits over safety?

The national vaccine attorneys at My Vaccine Lawyer have dedicated our careers to fighting for the victims of severe reactions to vaccines including Gardasil and Cervarix. We currently represent clients across the countries that have suffered various reactions to the HPV vaccination. If you believe you may have suffered an adverse reaction to a vaccine, please contact My Vaccine Lawyer at (800) 229-7704 for a free consultation.


https://www.japantimes.co.jp/news/2017/02/13/national/crime-legal/suit-opens-tokyo-court-cervical-cancer-vaccine-side-effects/notice how

NATIONAL / CRIME & LEGAL

Suit opens in Tokyo court over cervical cancer vaccine side effects

Twenty-eight girls and women suffering what they say are side effects from cervical cancer vaccines that were recommended by the government demanded compensation from the state and drugmakers Monday as their trial opened at the Tokyo District Court.

The plaintiffs, ranging in age from 15 to 22, said they have experienced a wide range of health problems, including pain all over their bodies and impaired mobility, after receiving the human papillomavirus (HPV) vaccines between 2010 and 2013.

Each is demanding ¥15 million in damages.

Erina Sonoda, a 20-year-old college student, said she started to suffer strong menstrual pain after receiving the second of three recommended shots of the Cervarix vaccine, and the pain spread to other parts of her body after the third vaccination.

Due to agonizing pain, Sonoda said she has difficulty walking without a cane and often must use a wheelchair.

“I felt acute pain as if someone was squashing my internal organs. … Such conditions have only gotten worse,” Sonoda told the court while sitting in a wheelchair.

“I received the shots because the government recommended it,” she said. “I want the government to take seriously its responsibility for causing us (to suffer from) such symptoms.”

Since last July, a total of 119 plaintiffs have filed similar suits with courts in Tokyo, Nagoya, Osaka and Fukuoka, according to Masumi Minaguchi, a lawyer representing the women.

The government and the drugmakers — GlaxoSmithKline PLC and Merck Sharp & Dohme Corp., who make the HPV vaccines Cervarix and Gardasil, respectively — sought Monday to dismiss the compensation claims.

Representatives of the drugmakers said the safety and effectiveness of the medicines against cervical cancer have been scientifically confirmed and denied there is any link between the alleged side effects and the vaccines.

The Health, Labor and Welfare Ministry began recommending in April 2013 that girls between 12 and 16 be vaccinated for cervical cancer. But the ministry halted the recommendation two months later following reports of side effects.

According to the ministry, 2,945 people out of the 3.39 million women who had received the shots by the end of last April have reported side effects.

A causal link between the HPV vaccines and reported symptoms remains unclear, and no scientific proof has been submitted.

A nationwide survey conducted by a health ministry research team between July and December 2015 found symptoms claimed as side effects of cervical cancer vaccines in both vaccinated and unvaccinated populations.

The team is conducting further detailed analysis of the data.

Cervical cancer is the second most common cause of cancer deaths in women under 40. Each year about 10,000 women develop the disease in Japan and around 2,900 die annually, according to the National Cancer Center.

The primary cause of cervical cancer is human papillomavirus, a common infection transmitted through sexual intercourse. The cervical cancer vaccines are believed to help prevent HPV.

In December 2015, the World Health Organization issued a statement criticizing the government’s decision to cease recommending the vaccine, saying that “policy decisions based on weak evidence, leading to lack of use of safe and effective vaccines, can result in real harm.”





https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967601/

Logo of miocLink to Publisher's site

. 2018; 113(8): e180063.
Published online 2018 May 28. doi: 10.1590/0074-02760180063
PMCID: PMC5967601
PMID: 29846395

Discrepancies in the evaluation of the safety of the human papillomavirus vaccine

The vaccine against the human papillomavirus (HPV) - HPV infection is the most common sexually transmitted viral infection. Several risk factors for HPV infection have been identified, and include genetic predisposition, immune status, co-infection with other sexually transmitted diseases, and smoking. Persistent infection with this virus is associated with squamous carcinoma of the cervix, oropharynx, anus, genitalia (vulva, vagina and penis), head, and neck. Approximately 90% of HPV infections resolve spontaneously through the immune system. Persistent infection with high-risk types 16 and 18 contributes to 20% and 50% of cervical cancers, respectively (). It is thus, not surprising that the first HPV vaccines were directed toward these genotypes (). There are 13 other high risk genotypes, including 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 (), whose presence in certain populations of Latin America (), could explain the discrepancy between the prevalence of 16/18 genotypes and the incidence of cervical cancer. A newer nonavalent vaccine has been approved by the Food and Drug Administration (FDA) to account for infections by seven high-risk HPV genotypes (16, 18, 31, 33, 45, 52, and 58) (), as the HPV vaccine does not provide protection against other types than those included in the vaccine.

Current HPV vaccines are based on virus-like particles, and are composed of self-assembled pentamers of the larger protein of the L1 capsid. HPV vaccines are prophylactic and are not therapeutic. The goal of prophylactic HPV vaccination is to avoid persistent infections that will progress to an invasive carcinoma. HPV vaccination would not be appropriate to elicit an anti-cancer response, since the tumor cells do not express significant levels of L1 protein. For treatment of cancers originating from HPV there is immunotherapy, which focuses on generating a cellular immune response against antigens associated with cellular transformation (). The HPV vaccine does not modify the cellular immunity that is responsible for eliminating the infected cells, rather it induces the production of antibodies against the L1 protein in blood. The two main HPV vaccines, Gardasil (Merck) and Cervarix (GSK), were approved in 2006 and in 2009, respectively, so it is still difficult to predict its long-term efficacy.

Rejection of the HPV vaccine - Even though more than 10 years have passed since its introduction, the global acceptance of the HPV vaccine remains low. In Latin America, the immunization rate is lower than expected (). In developed countries such as Canada, the rejection of HPV vaccination is high in both the lowest and the highest economic levels ().

Several countries in Latin America have shown a marked decrease in their immunization rates (). The initial recommendation of three intramuscular doses has now been reduced to two doses in a period of 6 to 24 months, in order to reduce costs and increase compliance (). Adherence to the three doses of the vaccine has also been low in Latin American countries, such as Brazil, Mexico, and Argentina (). This occurs after complaints of various symptoms, including suicides in Colombian girls after receiving the vaccine ().

Japan, after four years since its introduction, suspended the recommendation to immunize against HPV in 2014 (). The decision was made after reported cases of chronic pain and other symptoms. Despite the reviews claiming that these reported cases were not related to the vaccine, no agreement was reached between Japan and the World Health Organization (WHO). Japan has previously shown to have very stringent thresholds for risk acceptance. One example of such, occurred during the bovine spongiform encephalopathy crisis, where, Japan re-examined meat samples imported from the US regardless of the safety assurance from the United States Department of Agriculture (USDA) and ultimately decided to suspend the importation of meat from the United States.

Adverse reactions to the HPV vaccine - According to HPV vaccine manufacturers, the most common adverse reactions to Gardasil include pain, swelling, redness, stinging, bruising, bleeding at the injection site, and headache, fever, nausea, diarrhea, abdominal pain, and syncope (https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf). For Cervarix, local adverse reactions occurring in ≥ 20% of subjects are pain, redness, and swelling at the site of injection. The most common general adverse events in ≥ 20% of the subjects are fatigue, headache, myalgia, gastrointestinal symptoms, and arthralgia (FDA).

The most frequent reported symptoms of HPV vaccination are chronic pain with paresthesia, headaches, fatigue, and orthostatic intolerance (). Small series and isolated cases of complex regional pain syndrome (CRPS), postural orthostatic tachycardia syndrome (POTS), and fibromyalgia, have been reported after vaccination against HPV. These conditions are often difficult to diagnose, and show similar clinical characteristics ().

Apparently, dysfunction of the sympathetic nervous system plays an important role in the pathogenesis of these syndromes (). Ninety three percent of affected subjects continue to have disabling symptoms for more than four years, unable to return to school or work (). Other studies, nevertheless, have shown a lack of evidence of an association between HPV vaccine and CRPS () or fatigue ().

It should be mentioned that chronic arthropathy has also been observed with other vaccines, such as the rubella vaccine.

HPV vaccine safety - The recommendation for the use of HPV vaccine by the WHO is based on efficacy and effectiveness data (). The Global Advisory Committee for the Safety of Vaccines (GACVS) is an independent body composed of clinicians and expert scientists, who meet under the WHO to provide rigorous advice on the safety of vaccines of global importance. In its latest report, the committee has evaluated the risk of developing Guillain-Barré syndrome, concluding that the risk is no more than 1 case per 1 million vaccinated (). The committee has also found no evidence of causality between the HPV vaccine and SDRC or STPO, and considers that there is still no evidence suggestive of a causal association for the various symptoms (including pain and motor dysfunction) after reviewing data obtained from surveillance in Japan. A review of the HPV vaccine safety by the Centers for Disease Control and Prevention (CDC) found no difference in side effects between vaccinated and unvaccinated individuals (). In fact the CDC's Vaccine Adverse Event reporting System (VAERS) states that the HPV vaccine is very safe, and has not found any unexpected patterns in maternal or fetal outcomes ().

These conclusions, however, are based on records that should be interpreted with care, especially when assessing cases with non-specific diagnosis, for which there is not a clear consensus on the diagnostic criteria () (Fig. 1).

An external file that holds a picture, illustration, etc.
Object name is 0074-0276-mioc-113-08-e180063-gf01.jpg
discrepancies in the evaluation of the human papillomavirus (HPV) vaccine. Authorities from countries such as Japan and Colombia, made the decision to suspend the vaccination recommendation and re-evaluate the vaccine, due to a significant number of cases of rare or clinically undefined complications after reception of the vaccine. The World Health Organization, on the other hand, evaluated the safety of the vaccine using more defined categories, and made its recommendations based on the efficacy and effectiveness of the vaccine.

Despite these pronouncements on the safety of HPV vaccine, regions in Colombia have reported a disproportionate number of neuropathic pain cases (with respect to the expected reactions declared by the pharmaceutical company producing Gardasil) ().

It is important to note that the occurrence of demyelinating disease after vaccination, despite being low, is not negligible. This type of complication has been reported for multiple vaccines such as influenza, HPV, hepatitis A or B, rabies, measles, rubella, yellow fever, anthrax, meningococcus, and tetanus.

Post-vaccination syndromes: beyond adjuvants - The presence of viral nucleic acids can cause autoimmune phenomena (). HPV vaccines, however, are composed of proteins as we previously described. An adjuvant is a substance commonly used in vaccines in order to increase the immune response against an antigen. The quadrivalent vaccine of Gardasil (Merck) contains a simple adjuvant of aluminum hydroxide (225 mg). The nonavalent vaccine contains twice the concentration of adjuvant (500 mg of Aluminum)(). The Cervarix vaccine uses a proprietary adjuvant, 3-O-desacyl-4 monophosphoryl lipid A (AS04), which appears to be more potent ().

The term “ASIA” (Autoimmune/inflammatory Syndrome Induced by Adjuvants) describes a spectrum of clinical conditions that share similar signs and symptoms, including somatoform and dysautonomic post-vaccination phenomena (). With respect to the HPV vaccine, it has been estimated that the rate of ASIA syndrome is 3.6 cases per 100,000 doses of anti-HPV vaccine (95% CI 3.4-3.7). The most common clinical manifestations are pyrexia (58%), myalgia (27%) and arthralgia or arthritis (19%).

It would not be the first time that adjuvants in a vaccine cause an adverse reaction. The use of AS03 as an adjuvant in the Pandemix vaccine against the influenza virus was linked to the development of autoimmune narcolepsy.

A recent study, however, shows that aluminum present in the adjuvant does not play a role in cellular hypersensitivity (). On the other hand, a review of the adverse effects in clinical trials comparing women who received the bivalent vaccine vs. those who received the aluminum placebo, showed an increase in deaths in the vaccinated group. This result cautions of a projected greater systemic adverse effects with the nonavalent vaccine. Furthermore, there is also a report of autoimmune thrombocytopenia with antiphospholipid antibodies after HPV vaccination ().

Equally important, the absence of symptoms does not exclude the presence of an inflammatory phenomenon, with epipharingitis being found in all women examined after HPV vaccination in Japan (). This phenomenon is more severe if the patient has a predisposition to develop autoimmune diseases such as lupus () (Fig. 2). Another reported post-HPV vaccination syndrome is called multiple evanescent white dot syndrome, a rare retinopathy of unknown origin (). The favorable response to immunosuppressive therapy suggests an autoimmune phenomenon, or at least an imbalance in immune function (Fig. 2).

An external file that holds a picture, illustration, etc.
Object name is 0074-0276-mioc-113-08-e180063-gf02.jpg
differences in the response to adjuvants. To overcome the obstacle of low immunogenicity of an antigen, protein-based vaccines often use adjuvants to obtain adequate levels of protection. In individuals with a certain predisposition to the development of autoimmunity, the excessive immune response can trigger autoimmune phenomena.

This evidence justifies the call made in countries such as Colombia for the identification of predictive markers to develop autoimmune diseases in the population to be vaccinated against HPV.

In conclusion - Apart from cultural and religious barriers, the adverse effects to HPV vaccines must be re-evaluated, since the initial clinical trials of the first vaccines were tested in different populations than women in Latin America or Japan. The role of the host immunogenetic background in HPV infection and the recognition of HPV antigens () are important, and have been studied for decades. The benefit of vaccines is undoubtedly to reduce the incidence of infectious diseases, and in the case of HPV, prevent the development of persistent infections leading to cervical cancer. Even so, the side effects must be closely monitored, and reported without bias, to ensure that the benefits outweigh the risks.

REFERENCES

  • Bizjak M, Bruck O, Kanduc D, Praprotnik S, Shoenfeld Y. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Semin Hematol. 2016;53(Suppl. 1):S48–S50. [PubMed[]
  • Cervantes J, Lema C, Hurtado L, Andrade R, Quiroga G, Garcia G, et al. Prevalence of human papillomavirus infection in rural villages of the Bolivian Amazon. Rev Inst Med Trop São Paulo. 2003;45(3):131–135. [PubMed[]
  • Cervantes JL. Multiple human papillomavirus infection: don't forget the genetic background. J Infect Dis. 2011;204(11):1816–1817. [PubMed[]
  • Donegan K, Beau-Lejdstrom R, King B, Seabroke S, Thomson A, Bryan P. Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine. 2013;31(43):4961–4967. [PubMed[]
  • Feiring B, Laake I, Bakken IJ, Greve-Isdahl M, Wyller VB, Haberg SE, et al. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway. Vaccine. 2017;35(33):4203–4212. [PubMed[]
  • Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406–1417. [PMC free article] [PubMed[]
  • Goldenberg DL. Diagnosis and differential diagnosis of fibromyalgia. Am J Med. 2009;122(Suppl. 12):S14–S21. [PubMed[]
  • Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: vaccine efficacy. J Am Acad Dermatol. 2015;73(5):759–767. [PubMed[]
  • Hotta O, Tanaka A, Torigoe A, Imai K, Ieiri N, Japanese Focal Inflammation Research Group Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA) Immunol Res. 2017;65(1):66–71. [PubMed[]
  • Jeffs LS, Nitschke J, Tervaert JW, Peh CA, Hurtado PR. Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation. Clin Rheumatol. 2016;35(4):943–951. [PubMed[]
  • Kirby T. FDA approves new upgraded Gardasil 9. Lancet Oncol. 2015;16(2):e56 [PubMed[]
  • Larson HJ, Wilson R, Hanley S, Parys A, Paterson P. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation. Hum Vaccin Immunother. 2014;10(9):2543–2550. [PMC free article] [PubMed[]
  • Martínez-Lavin M, Martínez-Martínez LA, Reyes-Loyola P. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015;34(11):1981–1983. [PubMed[]
  • Martínez-Lavin M. Hypothesis: human papillomavirus vaccination syndrome - small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol. 2015;34(7):1165–1169. [PubMed[]
  • Moro PL, Zheteyeva Y, Lewis P, Shi J, Yue X, Museru OI, et al. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System 2006-2013. Vaccine. 2015;33(4):519–522. [PMC free article] [PubMed[]
  • Muñoz N, Reina JC, Sánchez GI. La vacuna contra el virus del papiloma humano: una gran arma para la prevención primaria del cáncer de cuello uterino. Colombia Med. 2008;39(2):196–2014. []
  • Ogino K, Kishi S, Yoshimura N. Multiple evanescent white dot syndrome after human papillomavirus vaccination. Case Rep Ophthalmol. 2014;5(1):38–43. [PMC free article] [PubMed[]
  • Palmieri B, Poddighe D, Vadala M, Laurino C, Carnovale C, Clementi E. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature. Immunol Res. 2017;65(1):106–116. [PMC free article] [PubMed[]
  • Poddighe D, Vadala M, Laurino C, Palmieri B. Somatoform and neurocognitive syndromes after HPV immunization are not associated to cell-mediated hypersensitivity to aluminum. Toxicol In Vitro. 2017;43:58–61. [PubMed[]
  • Remes O, Smith LM, Alvarado-Llano BE, Colley L, Levesque LE. Individual - and regional-level determinants of human papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study. BMC Public Health. 2014;14:1047–1047. [PMC free article] [PubMed[]
  • Sánchez-Gómez FJ, Hernández-Flórez LJ. La vacunación contra el vírus del papiloma humano en Colombia. Revista Geren Polit Salud. 2014;13(27):05–09. []
  • Skeate JG, Woodham AW, Einstein MH, da Silva DM, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016;12(6):1418–1429. [PMC free article] [PubMed[]
  • Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21(2):158–161. [PubMed[]
  • Tabakman R. El fracaso de la aplicación de la vacuna contra el virus del papiloma humano en Latinoamérica. Medscape. 2017. Available from: http://www.fasgo.org.ar/images/Fracaso_HPV.pdf.
  • Tomljenovic L, Colafrancesco S, Perricone C, Shoenfeld Y. Postural orthostatic tachycardia with chronic fatigue after HPV vaccination as part of the “autoimmune/auto-inflammatory syndrome induced by adjuvants”: case report and literature review. J Investig Med High Impact Case Rep. 2014;2(1) 2324709614527812. [PMC free article] [PubMed[]
  • Weinbaum CM, Cano M. HPV vaccination and complex regional pain syndrome: lack of evidence. EBioMedicine. 2015;2(9):1014–1015. [PMC free article] [PubMed[]
  • WHO - World Health Organization Human papillomavirus vaccines: WHO position paper, May 2017 - Recommendations. Vaccine. 2017a;35(43):5753–5755. [PubMed[]
  • WHO - World Health Organization Safety update of HPV vaccines. 2017b. Available from: http://www.who.int/vaccine_safety/committee/topics/hpv/June_2017/en/

Articles from Memórias do Instituto Oswaldo Cruz are provided here courtesy of Instituto Oswaldo Cruz

https://www.beasleyallen.com/matter/gardasil-and-cervarix/


Lead Expert of HPV Vaccine Tells the Truth About Gardasil and Cervarix

Dr. Diane Harper was a leading developer and expert responsible for the Phase II and Phase III safety and effectiveness studies, which gained the approval of the human papilloma virus ("HPV") vaccines, Gardasil and Cervarix. Since the HPV vaccine has been approved by the FDA and gained popularity, Dr. Harper has publicized the serious consequences, as well as the ineffectiveness, of these vaccines.

Dr. Harper made her shocking statement at the 4th International Conference on Vaccination, which took place on October 2, 2009 in Reston, Virginia. Reportedly, her speech was supposed to support the Gardasil and Cervarix vaccines, but instead she decided to clear her conscience about the deadly vaccines, in public, so she “could sleep at night.”

Dr. Harper explained in her presentation that the risk of cervical cancer in the U.S. is already very low and that vaccinations are unlikely to have any effect upon the rate of cervical cancer in the United States.  In fact, 70 percent of all HPV infections resolve themselves without treatment in a year, and the number rises to well over 90 percent in two years. Remarkably, all the trials of the vaccines were done on children aged 15 and older, despite them currently being marketed for 9-year-olds.

At least 15,037 girls have reported adverse side effects just from Gardasil to the Vaccine Adverse Event Reporting System (VAERS), and this number only reflects those who underwent all the requirements for reporting adverse reactions.  Moreover, according to the latest VAERS Report, 139 deaths from girls treated with the HPV related vaccinations are officially known. At the time of Dr. Harper’s speech, it was recorded to be 44 deaths.  Some of the other reported side effects include Guillain-Barre Syndrome, lupus, seizures, blood clots, and brain inflammation. In most cases, parents are not made aware of these risks.

Dr. Diane Harper went on to say, “About eight in every ten women who have been sexually active will have HPV at some stage of their life. Normally there are no symptoms, and in 98 percent of cases it clears itself. But in those cases where it doesn’t, and isn’t treated, it can lead to precancerous cells which may develop into cervical cancer.”

There is no actual evidence that the vaccine can prevent any cancer. From the manufacturers own admissions, the vaccine only works on 4 strains out of 40 for a specific venereal disease that dies on its own in a relatively short period, so the chance of it actually helping an individual is about the same as the chance of her being struck by lightning.  Is it really necessary for a 9-year-old girl to receive a vaccination for an extremely rare and symptomless venereal disease that the immune system usually kills anyway? Are pharmaceutical companies placing profits over safety?

The national vaccine attorneys at My Vaccine Lawyer have dedicated our careers to fighting for the victims of severe reactions to vaccines including Gardasil and Cervarix. We currently represent clients across the countries that have suffered various reactions to the HPV vaccination. If you believe you may have suffered an adverse reaction to a vaccine, please contact My Vaccine Lawyer at (800) 229-7704 for a free consultation.


https://www.myvaccinelawyer.com/blog/lead-expert-hpv-vaccine-tells-truth-gardasil-cervarix


Lead Expert of HPV Vaccine Tells the Truth About Gardasil and Cervarix

Dr. Diane Harper was a leading developer and expert responsible for the Phase II and Phase III safety and effectiveness studies, which gained the approval of the human papilloma virus ("HPV") vaccines, Gardasil and Cervarix. Since the HPV vaccine has been approved by the FDA and gained popularity, Dr. Harper has publicized the serious consequences, as well as the ineffectiveness, of these vaccines.

Dr. Harper made her shocking statement at the 4th International Conference on Vaccination, which took place on October 2, 2009 in Reston, Virginia. Reportedly, her speech was supposed to support the Gardasil and Cervarix vaccines, but instead she decided to clear her conscience about the deadly vaccines, in public, so she “could sleep at night.”

Dr. Harper explained in her presentation that the risk of cervical cancer in the U.S. is already very low and that vaccinations are unlikely to have any effect upon the rate of cervical cancer in the United States.  In fact, 70 percent of all HPV infections resolve themselves without treatment in a year, and the number rises to well over 90 percent in two years. Remarkably, all the trials of the vaccines were done on children aged 15 and older, despite them currently being marketed for 9-year-olds.

At least 15,037 girls have reported adverse side effects just from Gardasil to the Vaccine Adverse Event Reporting System (VAERS), and this number only reflects those who underwent all the requirements for reporting adverse reactions.  Moreover, according to the latest VAERS Report, 139 deaths from girls treated with the HPV related vaccinations are officially known. At the time of Dr. Harper’s speech, it was recorded to be 44 deaths.  Some of the other reported side effects include Guillain-Barre Syndrome, lupus, seizures, blood clots, and brain inflammation. In most cases, parents are not made aware of these risks.

Dr. Diane Harper went on to say, “About eight in every ten women who have been sexually active will have HPV at some stage of their life. Normally there are no symptoms, and in 98 percent of cases it clears itself. But in those cases where it doesn’t, and isn’t treated, it can lead to precancerous cells which may develop into cervical cancer.”

There is no actual evidence that the vaccine can prevent any cancer. From the manufacturers own admissions, the vaccine only works on 4 strains out of 40 for a specific venereal disease that dies on its own in a relatively short period, so the chance of it actually helping an individual is about the same as the chance of her being struck by lightning.  Is it really necessary for a 9-year-old girl to receive a vaccination for an extremely rare and symptomless venereal disease that the immune system usually kills anyway? Are pharmaceutical companies placing profits over safety?

The national vaccine attorneys at My Vaccine Lawyer have dedicated our careers to fighting for the victims of severe reactions to vaccines including Gardasil and Cervarix. We currently represent clients across the countries that have suffered various reactions to the HPV vaccination. If you believe you may have suffered an adverse reaction to a vaccine, please contact My Vaccine Lawyer at (800) 229-7704 for a free consultation.

https://www.google.com/search?newwindow=1&rlz=1C1CHBD_enUS903US903&sxsrf=ALeKk00E7kGMRudQEiECWbu0VXOlQ7nFuQ%3A1606389609354&ei=aY-_X4yQFcjq-gSx-


https://www.beasleyallen.com/contact/6GgCw&q=Cervarix+lawsuit&oq=Cervarix+lawsuit&gs_lcp=CgZwc3ktYWIQAzIFCAAQzQIyBQgAEM0CMgUIABDNAjoECAAQRzoHCAAQyQMQQzoECAAQQzoCCAA6BQgAEMkDOgYIABAWEB46BQghEKABOgcIIRAKEKABUMjTAliJ3gJg_eACaABwAngAgAGcAogB5wiSAQUzLjMuMpgBAKABAaoBB2d3cy13aXrIAQjAAQE&sclient=psy-ab&ved=0ahUKEwjM6KTQi6DtAhVItZ4KHbF9CLQQ4dUDCA0&uact=5














Notice how , in this video, they say that the vaccines should not be given to people who are allergic to aluminum (which is a KNOWN TOXIN)! Why are these girls and boys not warned, that they should get tested for these sensitivities, FIRST???






Mom questions safety of Gardasil



https://www.letstalkpublichealth.com/blog/gardasil-one-less-hbm

Picture
In recognition of Cervical Cancer Awareness Month, let’s talk about HPV and the ad campaign that first introduced the HPV vaccine to the world.
Merck first introduced the Gardasil vaccine with the One Less TV campaign. The campaign focused on empowering women and girls to become one less person with cervical cancer by deciding to get vaccinated. Due to the health behavior change element, Merck’s ad campaign provides a great case study for health communication and marketing. 

When planning a behavior change campaign, most public health communicators use a theoretical framework as the foundation for planning, implementation and evaluation. While the marketers behind One Less may not have used a behavioral health theory, retrospectively, this campaign aligns nicely with the Health Belief Model. You can break it down into four aims, targeted to the theoretical constructs:

Aim: Establish the threat of cervical cancer​ 
  • Message(s): “Every year in the US, thousands of women learn they have cervical cancer.​"
Aim: Establish the benefits and barriers of vaccination
  • ​​​​​​​​​Message(s): “Because now there’s Gardasil, the only vaccine that may help protect you from 4 types of human papillomavirus that may cause 70% of cervical cancer.” This also includes federally mandated information like: “Like all vaccines, Gardasil may not fully protect everyone.” 
Aim: Provide a clear cue to action
  • Message(s): “Ask your doctor about getting vaccinated with the only cervical cancer vaccine: Gardasil.”
Aim: Build up the self-efficacy of women and girls to perform the behavior (getting vaccinated) and overcome the health issue (cervical cancer)
  • ​​​​​​​​​Message(s): “With Gardasil, you could be one less.”

Each construct in the theory and the corresponding aim in the ad were important. Women needed to know that cervical was a relevant threat to them. They also needed to know that there was something they could do about it: getting vaccinated. Additionally, they needed information about getting vaccinated so they could decide if vaccination was for them (or their daughters). And lastly, they needed to feel like they could get vaccinated and successfully prevent cervical cancer.

Just as important as the messages, were the women and girls that delivered them. The advertising team behind the campaign was very deliberate in its casting for the ad. They needed the actresses to come off as cool, confident and taking charge of their health.  Anyone who didn't fit the bill was cut.

And lastly, to leave an impression, the advertising team came up with a catchy, rhythmic slogan: “O-N-E-L-E-S-S, I want to be one less, one less!”


Do you think they were successful with this ad? One study suggests that while the One Less ads were effective in conveying risk information, young women relied primarily on the recommendations of their mothers and medical providers when deciding whether or not to vaccinate. In other words, the information in the ad was not enough. The vaccination messages needed to come from mothers or providers. This may be why Merck followed up the One Less campaign with the I Chose TV ad campaign, which was aimed more towards parents and included adult women saying, "I chose to get my daughter vaccinated because…” They also made sure to include, “I chose to get my daughter vaccinated because I want her to be one less woman affected by cervical cancer," to tie into the One Less campaign theme.
UPDATE (3/6/20): Temple University's College of Public Health published an interesting article discussing how commercial ad campaigns like O-N-E-L-E-S-S have led to misperceptions about HPV. These campaigns frame HPV as cervical cancer prevention, making HPV seem like a women's health issue. But HPV is a sexual health issue and is a concern for both men and women. HPV can cause other types of cancers, and there are key people at risk for these other cancers, such as gay and bisexual men who are at risk for HPV-related anal cancer, that are unaware of their risk.
By: Monique Thornton, MPH
Picture
About the Author
Editor-in-chief at Let's Talk Public Health. I'm a public health communication and marketing professional fusing creative writing, health communication, public health, and behavior change theory. Let's talk social and digital media, edutainment, product development, and digital health.



In this video, the narrator talks about how the HPV vaccine does not protect girls from all forms of HPV, so they will STILL have to get yearly pap smears.

It is shown that regular pap smears can protect women againstcervical cancer, so.... 

What are we even doing this for? Shouldn't we all just make sure to get our pap smears??? What am I missing, here...


Should You Get the HPV Vaccine?


























No comments:

Post a Comment

Note: Only a member of this blog may post a comment.